Interestingly, approximately a quarter to half of ovarian cancers with germline BRCA1/BRCA2 mutations exhibit the reversion of the inherited mutation and chemoresistance after chemotherapy (47, 55, 56), suggesting that in vivo retrieval of BRCA function is a potent oncogenic event to resist unwanted DNA damage. The gene discussed is BRCA1; the disease is ovarian cancer.